Wayne State University Department of Dermatology, Wayne State University School of Medicine, Detroit, MI, USA.
Clin Cosmet Investig Dermatol. 2011;4:93-9. doi: 10.2147/CCID.S17917. Epub 2011 Jul 1.
Chronic plaque psoriasis is a systemic disease affecting over 3% of the population, and many patients are unsatisfied with their current treatment regimen. With advances in understanding of the pathophysiology of psoriasis, new therapeutic options are being developed. The newest of these agents, ustekinumab, offers patients rapid results and the convenience of four annual subcutaneous doses, with efficacy and safety profiles comparable with those of other biologics. However, ustekinumab has been on the market in the US for less than 2 years and will require years of extensive use before the full adverse event profile is fully understood. The purpose of this paper is to summarize the treatment options currently available for psoriasis, with an emphasis on ustekinumab in order to give prescribers an overview of the available data and allow them to make educated and informed prescribing decisions.
慢性斑块型银屑病是一种影响超过 3%人群的系统性疾病，许多患者对当前的治疗方案不满意。随着对银屑病病理生理学认识的提高，新的治疗选择正在开发中。这些新型药物中，乌司奴单抗为患者提供了快速的治疗效果和每年 4 次皮下注射的便利，其疗效和安全性与其他生物制剂相当。然而，乌司奴单抗在美国上市还不到 2 年，在充分了解其全部不良反应之前，还需要多年的广泛应用。本文旨在总结目前可用于治疗银屑病的治疗方案，重点介绍乌司奴单抗，以便为处方医生提供可用数据的概述，并使他们能够做出明智和知情的处方决策。
